Identification of serum biomarkers for premature ovarian failure

Lee, Da Hye; Pei, Chang-Zhu; Song, Jae Yun; Lee, Kyung Ju; Yun, Bo Hyon; Kwack, Kyu Bum; Lee, Eunil; Baek, Kwang Hyun

doi:10.1016/j.bbapap.2018.12.007

Cited by 15 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The filters included: full text and female and the publications in the English language and year=“2005-Current”. The abstracts of the articles were included as following criteria ( 1 ): BMSCs transplantation in treating premature ovarian failure ( 2 ). Only original research articles were included, but not reviews.…”

Section: Methodsmentioning

confidence: 99%

“…Premature ovarian failure (POF) refers to the decline of the ovarian function that occurs before the age of 40 in female. It is a clinical syndrome defined by oligomenorrhea or amenorrhea, increased gonadotropin levels, and decreased estradiol levels, and it is often accompanied by a variety of perimenopausal symptoms such as hot flashes, night sweats, alopecia, dry skin and mucous membranes, decreased libido, sleep disorders, irritability ( 1 , 2 ). The diagnosis of POF in clinical is usually based on FSH >40 IU/L, oligo/amenorrhea for 4-6 months in female under 40 years old, and hypoestrogenemia ( 3 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bone marrow mesenchymal stem cells in premature ovarian failure: Mechanisms and prospects

Huang

Zhu²,

Liu³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Premature ovarian failure (POF) is a common female reproductive disorder and characterized by menopause, increased gonadotropin levels and estrogen deficiency before the age of 40 years old. The etiologies and pathogenesis of POF are not fully clear. At present, hormone replacement therapy (HRT) is the main treatment options for POF. It helps to ameliorate perimenopausal symptoms and related health risks, but can’t restore ovarian function and fertility fundamentally. With the development of regenerative medicine, bone marrow mesenchymal stem cells (BMSCs) have shown great potential for the recovery of ovarian function and fertility based on the advantages of abundant sources, high capacity for self-renewal and differentiation, low immunogenicity and less ethical considerations. This systematic review aims to summarize the possible therapeutic mechanisms of BMSCs for POF. A detailed search strategy of preclinical studies and clinical trials on BMSCs and POF was performed on PubMed, MEDLINE, Web of Science and Embase database. A total of 21 studies were included in this review. Although the standardization of BMSCs need more explorations, there is no doubt that BMSCs transplantation may represent a prospective therapy for POF. It is hope to provide a theoretical basis for further research and treatment for POF.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Bone marrow mesenchymal stem cells in premature ovarian failure: Mechanisms and prospects

Huang

Zhu²,

Liu³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…5 The exosome within the structure and vessels of the placenta, including the various exosomal markers which may indicate the early diagnosis of different reproductive diseases. This summary includespolycystic ovarian syndrome (PCOS) [62, 66-69, 76, 78], uterine and reproductive inflammation [34,73,74], endometriosis [75,76], pre-mature ovarian failure (POF) [79][80][81][82]84], gestation diabetes mellitus (GDM) [85][86][87][88], and pre-eclampsia [74,[90][91][92][93][94]. These exosomal markers are possible milestones of the pathological responses which are undergone in these reproductive diseases and indicates that early diagnosis may indeed be a possibility previous clinical trials have indicated that more consistent and accurate diagnostic and prognostic tools may improve patient outcomes [90].…”

Section: Exosomal Isolation and Loading Methodsmentioning

confidence: 99%

The exosome: a review of current therapeutic roles and capabilities in human reproduction

Dimik

Abeysinghe

Logan

et al. 2022

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Exosomes are nano-vesicles (30–150 nm) which may be useful as therapeutic delivery vehicles and as diagnostic biomarkers. Exosomes are produced naturally within the human body and therefore are not prone to immunogenicity effects which would otherwise destroy unelicited foreign bodies. Clinically, they have been regarded as ideal candidates for applications relating to biomarker developments for the early detection of different diseases. Furthermore, exosomes may be of interest as potential drug delivery vehicles, which may improve factors such as bioavailability of loaded molecular cargo, side effect profiles, off-target effects, and pharmacokinetics of drug molecules. In this review, the therapeutic potential of exosomes and their use as clinical biomarkers for early diagnostics will be explored, alongside exosomes as therapeutic delivery vehicles. This review will evaluate techniques for cargo loading, and the capacity of loaded exosomes to improve various reproductive disease states. It becomes important, therefore, to consider factors such as loading efficiency, loading methods, cell viability, exosomal sources, exosome isolation, and the potential therapeutic benefits of exosomes. Issues related to targeted drug delivery will also be discussed. Finally, the variety of therapeutic cargo and the application of appropriate loading methods is explored, in the context of establishing clinical utility. Graphical abstract Exosomes have more recently been widely accpeted as potential tools for disease diagnostics and the targeted delivery of certain therapeutic molecules–and in due time exosomes will be utilised more commonly within the clinical setting. Specifically, exosomal biomarkers can be identified and related to various detrimental conditions which occur during pregnancy. Considering, this review will explore the potential future of exosomes as both diagnostic tools and therapeutic delivery vehicles to treat related conditions, including the challenges which exist towards incorporating exosomes within the clinical environment to benefit patients.

show abstract

“…In POI, measurements of serum levels of follicular stimulating (FSH) and anti-Müllerian (AMH) hormones, estradiol (E2) and inhibin B can be performed using standard protocols to assess the ovarian reserve [110]. A proteomic approach enlarged the list of possible candidates as biomarkers of POI with the identification of proteins with potential actions over reproductive functions (ceruloplasmin, complement C3, fibrinogen α, fibrinogen β, and sex hormone-binding globin SHBG) [111]. Although measurements of circulating endocrine hormones and other compounds can monitor the POI linked to CGG PM (FXPOI), they hardly discriminate between POI of different origin in the absence of a genetic test for FMR1 CGG repeats.…”

Section: Endocrine Biomarkers In Premutation Carriersmentioning

confidence: 99%

Molecular Pathogenesis and Peripheral Monitoring of Adult Fragile X-Associated Syndromes

Valor

Morales

Hervás-Corpión

et al. 2021

IJMS

View full text Add to dashboard Cite

Abnormal trinucleotide expansions cause rare disorders that compromise quality of life and, in some cases, lifespan. In particular, the expansions of the CGG-repeats stretch at the 5’-UTR of the Fragile X Mental Retardation 1 (FMR1) gene have pleiotropic effects that lead to a variety of Fragile X-associated syndromes: the neurodevelopmental Fragile X syndrome (FXS) in children, the late-onset neurodegenerative disorder Fragile X-associated tremor-ataxia syndrome (FXTAS) that mainly affects adult men, the Fragile X-associated primary ovarian insufficiency (FXPOI) in adult women, and a variety of psychiatric and affective disorders that are under the term of Fragile X-associated neuropsychiatric disorders (FXAND). In this review, we will describe the pathological mechanisms of the adult “gain-of-function” syndromes that are mainly caused by the toxic actions of CGG RNA and FMRpolyG peptide. There have been intensive attempts to identify reliable peripheral biomarkers to assess disease progression and onset of specific pathological traits. Mitochondrial dysfunction, altered miRNA expression, endocrine system failure, and impairment of the GABAergic transmission are some of the affectations that are susceptible to be tracked using peripheral blood for monitoring of the motor, cognitive, psychiatric and reproductive impairment of the CGG-expansion carriers. We provided some illustrative examples from our own cohort. Understanding the association between molecular pathogenesis and biomarkers dynamics will improve effective prognosis and clinical management of CGG-expansion carriers.

show abstract

Identification of serum biomarkers for premature ovarian failure

Cited by 15 publications

References 25 publications

Bone marrow mesenchymal stem cells in premature ovarian failure: Mechanisms and prospects

Bone marrow mesenchymal stem cells in premature ovarian failure: Mechanisms and prospects

The exosome: a review of current therapeutic roles and capabilities in human reproduction

Molecular Pathogenesis and Peripheral Monitoring of Adult Fragile X-Associated Syndromes

Contact Info

Product

Resources

About